Nasim Parsa1,2, Mouen A Khashab3. 1. Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, 1800 Orleans Street, Zayed Building, Suite 7125B, Baltimore, MD, 21287, USA. 2. Department of Internal Medicine, MedStar Harbor Hospital, Baltimore, MD, USA. 3. Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, 1800 Orleans Street, Zayed Building, Suite 7125B, Baltimore, MD, 21287, USA. mkhasha1@jhmi.edu.
Abstract
OPINION STATEMENT: PURPOSE OF THE REVIEW: Peroral endoscopic myotomy (POEM) is a novel minimally invasive technique that has emerged as the preferred option for the treatment of achalasia and spastic esophageal disorders (SED) at many centers around the world. In this article, we review and summarize the recent literature on POEM in patients with achalasia and SED. The current article is largely focused on the new developments and findings, extended applications, and long-term outcomes of POEM in patients with achalasia and SED. RECENT FINDINGS: POEM is a safe and effective therapy for patients with achalasia and SED. POEM is comparable to Heller myotomy (HM) in terms of safety, efficacy, and complications, including gastroesophageal reflux disease (GERD). Outcomes of POEM are excellent even in patients who had prior failed therapies for achalasia, including failed HM and prior POEM. Recent data also suggest the efficacy and safety of POEM in both pediatric and geriatric patients. GERD after POEM is common, and the majority of patients are asymptomatic. The management, goals of therapy, and long-term outcomes of GERD after POEM are unclear. Objective testing for all patients is recommended. POEM is a validated treatment for all patients with achalasia and SED. Candidates should be carefully selected and appropriately counseled on expected outcomes and the need for long-term surveillance.
OPINION STATEMENT: PURPOSE OF THE REVIEW: Peroral endoscopic myotomy (POEM) is a novel minimally invasive technique that has emerged as the preferred option for the treatment of achalasia and spastic esophageal disorders (SED) at many centers around the world. In this article, we review and summarize the recent literature on POEM in patients with achalasia and SED. The current article is largely focused on the new developments and findings, extended applications, and long-term outcomes of POEM in patients with achalasia and SED. RECENT FINDINGS: POEM is a safe and effective therapy for patients with achalasia and SED. POEM is comparable to Heller myotomy (HM) in terms of safety, efficacy, and complications, including gastroesophageal reflux disease (GERD). Outcomes of POEM are excellent even in patients who had prior failed therapies for achalasia, including failed HM and prior POEM. Recent data also suggest the efficacy and safety of POEM in both pediatric and geriatric patients. GERD after POEM is common, and the majority of patients are asymptomatic. The management, goals of therapy, and long-term outcomes of GERD after POEM are unclear. Objective testing for all patients is recommended. POEM is a validated treatment for all patients with achalasia and SED. Candidates should be carefully selected and appropriately counseled on expected outcomes and the need for long-term surveillance.
Authors: Yuki B Werner; Guido Costamagna; Lee L Swanström; Daniel von Renteln; Pietro Familiari; Ahmed M Sharata; Tania Noder; Guido Schachschal; Jan F Kersten; Thomas Rösch Journal: Gut Date: 2015-04-30 Impact factor: 23.059
Authors: Daniel Von Renteln; Karl-Hermann Fuchs; Paul Fockens; Peter Bauerfeind; Melina C Vassiliou; Yuki B Werner; Gerald Fried; Wolfram Breithaupt; Henriette Heinrich; Albert J Bredenoord; Jan F Kersten; Tessa Verlaan; Michael Trevisonno; Thomas Rösch Journal: Gastroenterology Date: 2013-05-09 Impact factor: 22.682
Authors: Ahmed M Sharata; Christy M Dunst; Radu Pescarus; Eran Shlomovitz; Aaron J T Wille; Kevin M Reavis; Lee L Swanström Journal: J Gastrointest Surg Date: 2014-09-03 Impact factor: 3.452
Authors: P H Zhou; Q L Li; L Q Yao; M D Xu; W F Chen; M Y Cai; J W Hu; L Li; Y Q Zhang; Y S Zhong; L L Ma; W Z Qin; Z Cui Journal: Endoscopy Date: 2013-02-06 Impact factor: 10.093
Authors: Ezra N Teitelbaum; Nathaniel J Soper; Byron F Santos; Fahd O Arafat; John E Pandolfino; Peter J Kahrilas; Ikuo Hirano; Eric S Hungness Journal: Surg Endosc Date: 2014-06-18 Impact factor: 4.584